Multistate analysis of skeletal events in patients with bone metastases

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Cook, Richard J ^a   Major, Pierre ^b   Berenson, ^c   Roodman, ^c   Suva, ^c   Body, ^c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID; PLACEBO;

BONE METASTASIS; BREAST CANCER; CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MODELS, THEORETICAL; MULTICENTER STUDIES; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33750732633     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0654     Document Type: Review

References (18)

1. Major P, Cook RJ. Challenges in the analysis of multiple events in oncology. In: Singh G, Rabbanis SA, editors. Bone metastases: experimental and clinical aspects. Totowa (NJ): Humana Press; 2004.
2. Major P, Cook RJ. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25:S1-9.
3. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001;93:534-8.
4. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44.
5. Kalbfleisch JD, Prentice R L. The statistical analysis of failure time data. New York: Wiley; 2002.
6. Lawless JF. Statistical models and methods for lifetime data. 2nd edition. New York: Wiley; 2003.
7. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.
8. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag; 1993.
9. Aalen O, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Statist 1987;5:141-50.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
11. Crowder MJ. Classical competing risks. Boca Raton: CRC Press; 2001.
12. Aalen O, Farewell VT, de Angelis D, Day NE, Gill ON. A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales. Stat Med 1998;19:2191-210.
13. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994;47:1-2.
14. Aalen O, Borgan O, Fekjaer H. Covariate adjustment of event histories estimated from Markov chains: the additive approach. Biometrics 2001;57:993-1001.
15. Datta S, Satten GA. Validity of the Aalen-Johansen estimators of stage occupation probabilities and Nelson-Aalen estimators of integrated transition hazards for non-Markov models. Stat Probab Lett 2001;55:403-11.
16. Scott M, Mocks J, Givens S, Kohler W, Maurer J, Budde M. Morbidity measures in the presence of recurrent composite endpoints. Pharm Stat 2003;2:39-49.
17. Ghosh D, Lin DY Nonparametric analysis of recurrent events and death. Biometrics 2000;56:554-62.
18. Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population based study. J Bone Mineral Res 2005;20:487-93.